Other languages Biosergen AB

Equities

BIOSGN

SE0016013460

Market Closed - Nasdaq Stockholm Other stock markets 14:39:32 03/05/2024 BST			5-day change	1st Jan Change
0.346 ^SEK	+3.59%		+1.47%	-60.68%

04-09	Biosergen to Issue New Units as Compensation Under Rights Issue	MT
03-27	Biosergen Raises SEK26.4 Million via Rights Issue	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biosergen to Issue New Units as Compensation Under Rights Issue	04-09
Biosergen Raises SEK26.4 Million via Rights Issue	03-27
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-29
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	02-12
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection	02-12
Biosergen Seeks Fresh Funds from Rights Offering, Secures Loan from Major Shareholder	01-31
Biosergen AB Announces CEO Changes	01-12
Biosergen AB Announces Transition of Peder M. Andersen into A Chief Medical Officer Role	01-12
Biosergen Conducts A New Phase 1B Study in Patients with Invasive Fungal Infections with Its Drug Candidate Bsg005 Together with Alkem	01-12
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate	12-12
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30
Biosergen AB Announces Abstract About the Drug Candidate BSG005	23/10/23
Biosergen, Alkem Laboratories Partner to Launch Clinical Trial of Fungal Disease Treatment in India	25/09/23
Alkem Laboratories Limited and Biosergen AB Enter into a Co-Development and License Agreement	25/09/23
Biosergen AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Biosergen AB Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23
Biosergen AB Announces Lena Degling Wikingsson and Hanne Mette Dyrlie Kristensen Declines Re-Election as Board Members	31/05/23
Biosergen Provides Phase 2 Clinical Development Strategy Update	29/03/23
Biosergen AB announces Positive Topline Data from Phase 1 Study of Bsg005 Shows It Is Safe and Well Tolerated. It Gives Hope for A Change in the Treatment Paradigm of Patients with Invasive Fungal Infections	13/03/23
Biosergen Proceeds with Phase 1 Anti-Fungal Drug Trial	16/01/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biosergen AB

Equities

BIOSGN

SE0016013460

Other languages

Filters